Previous close | 0.0360 |
Open | 0.0360 |
Bid | 0.0350 x N/A |
Ask | 0.0370 x N/A |
Day's range | 0.0350 - 0.0360 |
52-week range | 0.0270 - 0.1464 |
Volume | |
Avg. volume | 1,810,011 |
Market cap | 37.013M |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 0.62 |
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024Option for Lantheus to invest a further A$7.5m within 6 months on the same termsLantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm The
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC). The dose escalation trial of RAD204, which targets PDL1-p
Radiopharm Theranostics ( ASX:RAD ) Full Year 2023 Results Key Financial Results Net loss: AU$34.6m (loss widened by...